Cargando…

Opioid-Induced Hypogonadism in the United States

OBJECTIVE: To examine the incidence of screening, diagnosis, and treatment of hypogonadism among men treated with opioids in the United States. PATIENTS AND METHODS: Using one of the nation's largest commercial insurance databases, we identified 53,888 men aged 20 years or older who had 90 or m...

Descripción completa

Detalles Bibliográficos
Autores principales: Baillargeon, Jacques, Raji, Mukaila A., Urban, Randall J., Lopez, David S., Williams, Stephen B., Westra, Jordan R., Kuo, Yong-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713891/
https://www.ncbi.nlm.nih.gov/pubmed/31485565
http://dx.doi.org/10.1016/j.mayocpiqo.2019.06.007
_version_ 1783446955763957760
author Baillargeon, Jacques
Raji, Mukaila A.
Urban, Randall J.
Lopez, David S.
Williams, Stephen B.
Westra, Jordan R.
Kuo, Yong-Fang
author_facet Baillargeon, Jacques
Raji, Mukaila A.
Urban, Randall J.
Lopez, David S.
Williams, Stephen B.
Westra, Jordan R.
Kuo, Yong-Fang
author_sort Baillargeon, Jacques
collection PubMed
description OBJECTIVE: To examine the incidence of screening, diagnosis, and treatment of hypogonadism among men treated with opioids in the United States. PATIENTS AND METHODS: Using one of the nation's largest commercial insurance databases, we identified 53,888 men aged 20 years or older who had 90 or more days of opioid prescriptions in a single 12-month period between January 1, 2010, and December 31, 2017, with no history of hypogonadism or testosterone therapy in the preceding 12 months. We matched this cohort to 53,888 men with 14 or fewer days of opioid prescriptions based on age, opioid initiation date, opioid indication, and comparable exclusion criteria. We assessed whether men, 14 or fewer days after initiation of opioid treatment, received a serum testosterone test, a diagnosis of hypogonadism, or a prescription for testosterone therapy. All men were followed up until they lost coverage from the commercial insurance plan, experienced one of the study outcomes, or the end of study (December 31, 2017). RESULTS: In the multivariable analyses—adjusting for age, year of opioid initiation, region, comorbid disease, glucocorticoid use, and health care utilization—the 53,888 prolonged opioid users, in comparison with 53,888 short-term users, had an increased incidence of serum testosterone screening (5991 [17.15%; 95% CI, 16.70%-17.61%] vs 3514 [11.55%; 95% CI, 11.11%-12.01%] at 5 years; hazard ratio [HR], 1.46; 95% CI, 1.38-1.55), hypogonadism diagnosis (3125 [9.44%; 95% CI, 9.09%-9.80%] vs 1421 [4.85%; 95% CI, 4.55%-5.16%; HR, 1.74; 95% CI, 1.60-1.90]), and receipt of testosterone therapy (1919 [5.76%; 95% CI, 5.49%-6.05%] vs 631 [2.21%; 95% CI, 2.04%-2.43%; HR, 2.41; 95% CI, 2.13-2.74]). Each of these findings persisted across multiple sensitivity analyses. CONCLUSION: Prolonged opioid exposure was associated with increased rates of screening, diagnosis, and treatment for opioid-induced hypogonadism, but these rates were much lower than expected based on previous serum-based studies.
format Online
Article
Text
id pubmed-6713891
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67138912019-09-04 Opioid-Induced Hypogonadism in the United States Baillargeon, Jacques Raji, Mukaila A. Urban, Randall J. Lopez, David S. Williams, Stephen B. Westra, Jordan R. Kuo, Yong-Fang Mayo Clin Proc Innov Qual Outcomes Original Article OBJECTIVE: To examine the incidence of screening, diagnosis, and treatment of hypogonadism among men treated with opioids in the United States. PATIENTS AND METHODS: Using one of the nation's largest commercial insurance databases, we identified 53,888 men aged 20 years or older who had 90 or more days of opioid prescriptions in a single 12-month period between January 1, 2010, and December 31, 2017, with no history of hypogonadism or testosterone therapy in the preceding 12 months. We matched this cohort to 53,888 men with 14 or fewer days of opioid prescriptions based on age, opioid initiation date, opioid indication, and comparable exclusion criteria. We assessed whether men, 14 or fewer days after initiation of opioid treatment, received a serum testosterone test, a diagnosis of hypogonadism, or a prescription for testosterone therapy. All men were followed up until they lost coverage from the commercial insurance plan, experienced one of the study outcomes, or the end of study (December 31, 2017). RESULTS: In the multivariable analyses—adjusting for age, year of opioid initiation, region, comorbid disease, glucocorticoid use, and health care utilization—the 53,888 prolonged opioid users, in comparison with 53,888 short-term users, had an increased incidence of serum testosterone screening (5991 [17.15%; 95% CI, 16.70%-17.61%] vs 3514 [11.55%; 95% CI, 11.11%-12.01%] at 5 years; hazard ratio [HR], 1.46; 95% CI, 1.38-1.55), hypogonadism diagnosis (3125 [9.44%; 95% CI, 9.09%-9.80%] vs 1421 [4.85%; 95% CI, 4.55%-5.16%; HR, 1.74; 95% CI, 1.60-1.90]), and receipt of testosterone therapy (1919 [5.76%; 95% CI, 5.49%-6.05%] vs 631 [2.21%; 95% CI, 2.04%-2.43%; HR, 2.41; 95% CI, 2.13-2.74]). Each of these findings persisted across multiple sensitivity analyses. CONCLUSION: Prolonged opioid exposure was associated with increased rates of screening, diagnosis, and treatment for opioid-induced hypogonadism, but these rates were much lower than expected based on previous serum-based studies. Elsevier 2019-08-23 /pmc/articles/PMC6713891/ /pubmed/31485565 http://dx.doi.org/10.1016/j.mayocpiqo.2019.06.007 Text en © 2019 THE AUTHORS https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Baillargeon, Jacques
Raji, Mukaila A.
Urban, Randall J.
Lopez, David S.
Williams, Stephen B.
Westra, Jordan R.
Kuo, Yong-Fang
Opioid-Induced Hypogonadism in the United States
title Opioid-Induced Hypogonadism in the United States
title_full Opioid-Induced Hypogonadism in the United States
title_fullStr Opioid-Induced Hypogonadism in the United States
title_full_unstemmed Opioid-Induced Hypogonadism in the United States
title_short Opioid-Induced Hypogonadism in the United States
title_sort opioid-induced hypogonadism in the united states
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713891/
https://www.ncbi.nlm.nih.gov/pubmed/31485565
http://dx.doi.org/10.1016/j.mayocpiqo.2019.06.007
work_keys_str_mv AT baillargeonjacques opioidinducedhypogonadismintheunitedstates
AT rajimukailaa opioidinducedhypogonadismintheunitedstates
AT urbanrandallj opioidinducedhypogonadismintheunitedstates
AT lopezdavids opioidinducedhypogonadismintheunitedstates
AT williamsstephenb opioidinducedhypogonadismintheunitedstates
AT westrajordanr opioidinducedhypogonadismintheunitedstates
AT kuoyongfang opioidinducedhypogonadismintheunitedstates